Table 1.
Baseline characteristics of COPD patients classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
| All COPD patients (n = 122) | GOLD spirometric severity | |||
|---|---|---|---|---|
| I + II (n = 51) | III + IV (n = 71) | p-value | ||
| Age, y | 74 (6) [75 (70; 78)] | 75 (5) | 73 (6) [74 (70; 78)] | 0.2253 |
| Sex, male/female (n) | 112/10 | 47/4 | 65/6 | 0.9040 |
| BMI, kg ⋅ m− 2 | 21.5 (3.3) | 22.2 (3.1) | 21.0 (3.4) | 0.0322 |
| Pulmonary function test | ||||
| FEV1, L | 1.27 (0.58) [1.09 (0.86; 1.58)] | 1.81 (0.52) [1.71 (1.49; 2.14)] | 0.88 (0.19) | < 0.0001 |
| %FEV1, % predicted | 50.8 (22.4) [45.6 (35.2; 63.7)] | 72.0 (18.0) [67.9 (57.6; 82.6)] | 35.6 (8.4) | < 0.0001 |
| FEV1/FVC, % | 42.2 (12.2) [40.6 (31.9;49.3)] | 51.8 (10.0) [50.0 (43.8; 60.3)] | 35.3 (8.2) [32.9 (29.9; 40.0)] | < 0.0001 |
| VC, L | 3.05 (0.77) | 3.50 (0.68) | 2.72 (0.65) | < 0.0001 |
| %VC, % | 99.0 (23.1) | 113.8 (122.1) | 88.5 (20.6) | < 0.0001 |
| IC, L | 1.96 (0.52) | 2.27 (0.48) | 1.73 (0.43) | < 0.0001 |
| Medications (n) | ||||
| LAMA | 102 | 37 | 65 | 0.0052 |
| LABA | 92 | 31 | 61 | 0.0015 |
| ICS | 64 | 21 | 43 | 0.0344 |
| Triple inhalation therapy | 45 | 10 | 35 | 0.0008 |
Data are presented as means (standard deviation) or [medians (interquartile range: 25th percentile to 75th percentile)], unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; IC: inspiratory capacity; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; VC: vital capacity. Medications are presented separately. Pulmonary function tests were performed after bronchodilator administration